CDC25A/NF-κB-IN-1
CDC25A/NF-κB-IN-1 is an effective dual-target inhibitor of CDC25A and NF-κB, and is a prodrug of Pt(IV). CDC25A/NF-κB-IN-1 has anticancer activity and low cytotoxicity to normal cells. CDC25A/NF-κB-IN-1 can trigger a variety of anticancer mechanisms, including S phase cell cycle arrest, mitochondrial endogenous apoptosis, endoplasmic reticulum stress, autophagy-dependent ferroptosis. CDC25A/NF-κB-IN-1 has good safety and can be used for ovarian cancer research.
For research use only. We do not sell to patients.
- Formula: C18H23Cl4N3O6Pt
- Molecular Weight:714.29
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Caspase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
Caspase-9 |
Bcl-2 |
Bax |
eIF2-α |
Cdc25A |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2780 | IC50 |
2.3 μM
|
Exhibits potent antiproliferative activity against A2780 for 48h.
Exhibits potent antiproliferative activity against A2780 for 48h.
|
42275647 |
| HeLa | IC50 |
9.1 μM
|
Exhibits potent antiproliferative activity against HeLa for 48h.
Exhibits potent antiproliferative activity against HeLa for 48h.
|
42275647 |
| HepG2 | IC50 |
11.0 μM
|
Exhibits potent antiproliferative activity against HepG2 for 48h.
Exhibits potent antiproliferative activity against HepG2 for 48h.
|
42275647 |
| A549 | IC50 |
13.4 μM
|
Exhibits potent antiproliferative activity against A549 for 48h.
Exhibits potent antiproliferative activity against A549 for 48h.
|
42275647 |
| HCT-116 | IC50 |
23.3 μM
|
Exhibits potent antiproliferative activity against HCT116 for 48h.
Exhibits potent antiproliferative activity against HCT116 for 48h.
|
42275647 |
In Vitro
CDC25A/NF-κB-IN-1 (complexe Pt6; 48 h) exhibits potent antiproliferative activity against A2780, HeLa, HepG2, A549 and HCT116 cells, with IC50 values of 2.3, 9.1, 11.0, 13.4 and 23.3 μM, respectively, while showing low cytotoxicity against normal WI-38 fibroblasts (IC50 = 38.4 μM)[1].
CDC25A/NF-κB-IN-1 (10 μM; 24 h) shows higher cellular uptake in A2780 cells than Cisplatin (HY-17394), with Pt accumulation in the cytoplasm, mitochondria, and nucleus at 71.8, 88.9, and 98.3 ng, respectively[1].
CDC25A/NF-κB-IN-1 (1-4 μM; 24 h) decreases intracellular GSH levels in A2780 cells in a concentration-dependent manner, with GSH relative contents reduced to approximately 78%, 56%, and 44% at 1, 2, and 4 μM, respectively, compared to the control group (100%)[1].
CDC25A/NF-κB-IN-1 (4 μM; 24 h) significantly reduces CDC25A protein levels and increases γ-H2AX levels in A2780 cells[1].
CDC25A/NF-κB-IN-1 (1-4 μM; 24 h) induces S-phase cell cycle arrest in A2780 cells (the proportion of S-phase cells increases from 23.8% to 67.5%) and downregulates CDK2 and Cyclin A levels[1].
CDC25A/NF-κB-IN-1 (0.5-4 μM; 24 h) induces concentration-dependent apoptosis in A2780 cells (the apoptosis rate increases from 9.8% to 78.5%) and upregulates p53 expression; it also increases γ-H2AX levels in a concentration-dependent manner[1].
CDC25A/NF-κB-IN-1 (1-4 μM; 24 h) induces a concentration-dependent decrease in mitochondrial membrane potential (the proportion of cells with decreased MMP increases from 1.6% to 33.4%) and ROS accumulation in A2780 cells, and upregulates the expression of Bax, Cyt c, and caspase-9, while downregulating Bcl-2 expression[1].
CDC25A/NF-κB-IN-1 (2-4 μM; 24 h) upregulates the expression of endoplasmic reticulum stress-related proteins CHOP, p-PERK, and p-eIF2α in A2780 cells[1].
CDC25A/NF-κB-IN-1 (0.1-0.4 μM; 10 d) inhibits colony formation in A2780 cells in a concentration-dependent manner[1].
CDC25A/NF-κB-IN-1 (1-4 μM; 24 h) inhibits cell migration in A2780 cells, decreasing the migration rate from 58.2% to 19.7%[1].
CDC25A/NF-κB-IN-1 (1-4 μM; 24 h) inhibits cell invasion in A2780 cells in a concentration-dependent manner[1].
CDC25A/NF-κB-IN-1 shows a docking affinity of -9.4 kcal/mol to NF-κB (P65) protein, with an equilibrium dissociation constant (KD) of 30.8 nM[1].
CDC25A/NF-κB-IN-1 (4 μM; 24 h) downregulates the expression of p-P65, p-IκBα, and p-IKKβ in TNF-α-stimulated A2780 cells, inhibiting the NF-κB signaling pathway[1].
CDC25A/NF-κB-IN-1 (1-4 μM; 24 h) induces concentration-dependent lipid peroxidation and autophagosome formation in A2780 cells, downregulates GPX4 and SLC7A11 expression, upregulates LC3-I/II expression, and induces p62 degradation; these effects can be reversed by Ferrostatin-1 (Fer 1) (HY-100579) and Chloroquine (CQ) (HY-17589A)[1].
CDC25A/NF-κB-IN-1 (4 μM; 24 h) induces autophagy-dependent ferroptosis in A2780 cells, and combined treatment with CQ attenuates lipid peroxidation and restores GPX4 and SLC7A11 expression[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:A2780 cells
-
Concentration:4 μM (Pt6), 10 μM (c2), 10 μM + 10 μM (c2 + CDDP), 10 μM (CDDP)
-
Incubation Time:24 h
-
Result:Markedly depleted CDC25A protein levels and significantly increased γ-H2AX levels (DNA damage marker). The CDC25A fluorescent signal was attenuated following treatment, ranked as c2 > c2 + CDDP > Pt6 > control.
-
Cell Line:A2780 cells
-
Concentration:1, 2, and 4 μM
-
Incubation Time:24 h
-
Result:Induced dose-dependent S-phase arrest, with S-phase population increasing from 23.8% (control) to 41.9%, 53.0%, and 67.5% at 1, 2, and 4 μM, respectively, accompanied by decreases in G0/G1 fraction.
-
Cell Line:A2780 cells
-
Concentration:2 and 4 μM
-
Incubation Time:24 h
-
Result:Significantly upregulated pro-apoptotic proteins Bax, Cytm-c, and caspase-9 while downregulating the anti-apoptotic protein Bcl-2, indicating activation of the intrinsic mitochondrial apoptotic pathway.
-
Cell Line:A2780 cells
-
Concentration:2 and 4 μM
-
Incubation Time:24 h
-
Result:Remarkably upregulated the expression of ER stress-related proteins CHOP, p-PERK, and p-eIF2α, demonstrating effective induction of ER stress.
-
Cell Line:A2780 cells
-
Concentration:0.1, 0.2, and 0.4 μM
-
Incubation Time:10 days
-
Result:Significantly reduced colony formation in a concentration-dependent manner at low concentrations.
-
Cell Line:A2780 cells
-
Concentration:1, 2, and 4 μM
-
Incubation Time:24 h
-
Result:Effectively inhibited cell migration, resulting in decreased migration rates of 38.9%, 27.6%, and 19.7%, compared to the control group (58.2%).
-
Cell Line:A2780 cells
-
Concentration:4 μM (Pt6), 10 μM (c2), 10 μM + 10 μM (c2 + CDDP), 10 μM (CDDP)
-
Incubation Time:24h (pretreated with 50 ng/mL TNF-α for 6 h)
-
Result:Effectively suppressed p65 protein expression. Significantly downregulated phosphorylated NF-κB pathway proteins including p-P65 (p-NF-κB), p-IκBα, and p-IKKβ.
-
Cell Line:A2780 cells
-
Concentration:2 and 4 μM
-
Incubation Time:24 h
-
Result:Significantly downregulated GPX4 and SLC7A11 levels (ferroptosis markers), upregulated LC3-I/II expression, and induced obvious p62 degradation (autophagy markers). These effects were reversed by Fer-1 (ferroptosis inhibitor) and CQ (autophagy inhibitor).
-
Cell Line:A2780 cells
-
Concentration:4 μM alone or in combination with Fer-1 (2 μM) or CQ (2 μM)
-
Incubation Time:24 h
-
Result:Cell viability was obviously increased by both Fer-1 and CQ in cells treated with the compound, confirming that cancer cell death is induced at least in part through the promotion of ferroptosis and autophagy.
-
Cell Line:A2780 cells
-
Concentration:1, 2, and 4 μM
-
Incubation Time:24 h
-
Result:Showed a dose-dependent inhibitory effect on cell invasion at all tested concentrations.
-
Cell Line:A2780 cells
-
Concentration:0.5, 1, 2, 3, and 4 μM
-
Incubation Time:24 h
-
Result:Induced concentration-dependent apoptosis, with total apoptosis rates ranging from 9.8 ± 1.5% to 78.5 ± 5.7%. Viable cells decreased from 96.1% to 21.5%, while early and late apoptotic populations increased dose-dependently.
Parmacokinetics
| Species | Dose | Route | T1/2 | CL | AUC0-∞ | AUC0-12 |
|---|---|---|---|---|---|---|
| Mice[1] | 9.5 mg/kg | i.v. | 5.2 h | 0.26 L/h/kg | 8699 μg/L·h | 7616.7 μg/L·h |
In Vivo
CDC25A/NF-κB-IN-1 (compound Pt6; healthy Kunming mice; 8-24 mg/kg; intraperitoneal injection; every 2 days for 14 days) shows good safety, with stable body weight and no major organ damage; doses of 20 and 24 mg/kg cause mortality, while 16 mg/kg induces sharp body weight loss without mortality[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:
-
Dosage:8 mg/kg, 16 mg/kg (MTD)
-
Administration:Intraperitoneal injection (i.p.); seven times over 14 days
-
Result:Tumor growth was significantly inhibited in a dose-dependent manner, with tumor volumes suppressed to 237.6 mm3 (8 mg/kg) and 160.1 mm³ (16 mg/kg), corresponding to TGI rates of 77.8% and 85.6%, respectively[1]. Superior antitumor efficacy was demonstrated [1]. Mice in the 8 mg/kg group exhibited stable body weight gain, with less body weight gain suppression[1]. No significant reduction in organ weights was observed in the experimental groups compared to the control group[1]. H&E staining of tumor tissues revealed nuclear pyknosis, disordered growth, and abundant apoptotic cells in the experimental groups compared to the cisplatin and c2 + cisplatin groups[1]. No obvious damage was observed in major organs (heart, liver, spleen, lungs, and kidneys) in the experimental groups[1]. Higher Pt levels were accumulated in tumors of the experimental groups (8 mg/kg and 16 mg/kg) compared to the cisplatin and c2 + cisplatin groups[1]. Pt was predominantly distributed in the kidney and liver, similar to the cisplatin group[1].
-
Animal Model:Healthy Kunming (KM) mice[1]
-
Dosage:8 mg/kg, 12 mg/kg, 16 mg/kg (MTD), 20 mg/kg, 24 mg/kg
-
Administration:Intraperitoneal injection (i.p.); every 2 days for 14 days
-
Result:Mice receiving 8 mg/kg exhibited more stable body weight gain than those in the Cisplatin (HY-17394) and c2 + Cisplatin positive control groups[1]. Mice treated with 12 mg/kg showed comparable weight changes to the Cisplatin and c2 + Cisplatin groups[1]. Administration at 20 and 24 mg/kg caused death in some mice within the 14-day period[1]. At 16 mg/kg, no mortality was observed; however, it induced a sharp decline in body weight, establishing the maximum tolerated dose (MTD) at approximately 16 mg/kg[1]. H&E staining of organs (heart, liver, spleen, lungs, and kidneys) from mice treated with Pt6 (8 mg/kg and 16 mg/kg) showed no organ damage compared to the control, Cisplatin, and c2 + Cisplatin groups[1].
Chemical Information
-
Molecular Weight 714.29
-
Formula C18H23Cl4N3O6Pt
-
SMILES
O=C1C(NCCCOC(CCCC(O[Pt](Cl)(Cl)([NH3])([NH3])Cl)=O)=O)=C(Cl)C(C2=CC=CC=C21)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- CDC25A/NF-κB-IN-1
- CDK
- NF-κB
- Caspase
- Autophagy
- Bcl-2 Family
- Atg8/LC3
- p62
- PERK
- Eukaryotic Initiation Factor (eIF)
- Apoptosis
- Ferroptosis
- CDC25A inhibitor
- NF-κB inhibitor
- dual inhibitor
- Pt(IV) prodrug
- 1,4-naphthoquinone
- A2780
- HeLa
- HepG2
- A549
- HCT116
- WI-38
- ovarian cancer
- cell cycle arrest
- apoptosis
- ferroptosis
- autophagy
- ER stress
- mitochondrial damage
- DNA damage
- A2780 xenograft model
- Inhibitor
- inhibitor
- inhibit